Akari Therapeutics, Plc AKTX
Set alert
7.84 USD -0.41 -4.97%
At close · Nov 2
8.07 +0.23 +2.89%
After hours · Nov 2, 4:00 PM ET
7.57 Day range 8.40
3.02 52-week range 33.60
- YTD
- -32.18%
- 1 year
- -73.87%
- Open
- 8.40
- Prev close
- 8.25
- Mkt cap
- 17.92M
- Vol
- 11.86K
- Avg vol
- 62.83K
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 7.57
- High
- 8.40
- Forward P/E
- -0.29
- Beta
- 0.95
- Short ratio
- 1.92
- Inst. own
- 0.51%
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 6, 2024
- 50-d avg
- 1.78
- 200-d avg
- 2.41
- 1y target
- 0.00
2Y chart
Events in this range
- Mar 31, 2026Split: 1 for 40
Signals (100)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Nov 2, 2026 | 8 hours ago |
| SMA: Bearish | Oct 29, 2026 | 4 days ago |
| SMA: Bullish | Oct 28, 2026 | 5 days ago |
| MACD: Buy Signal | Oct 28, 2026 | 5 days ago |
| MACD: Sell Signal | Oct 26, 2026 | 1 week ago |
| SMA: Bearish | Oct 21, 2026 | 1 week ago |
| SMA: Bearish | Oct 21, 2026 | 1 week ago |
| SMA: Bullish | Oct 19, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 19, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 19, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
| SMA: Bearish | Sep 30, 2026 | 1 month ago |
| SMA: Bullish | Sep 22, 2026 | 1 month ago |
| SMA: Bullish | Sep 21, 2026 | 1 month ago |
| SMA: Bearish | Sep 18, 2026 | 1 month ago |
| SMA: Bearish | Sep 18, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 17, 2026 | 1 month ago |
| SMA: Bullish | Aug 28, 2026 | 2 months ago |
| SMA: Bullish | Aug 28, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 14, 2026 | 2 months ago |
| SMA: Bearish | Jul 17, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 16, 2026 | 3 months ago |
| SMA: Bearish | Jul 8, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 8, 2026 | 3 months ago |
| SMA: Bullish | Jul 7, 2026 | 3 months ago |
| MACD: Sell Signal | Jun 10, 2026 | 4 months ago |
| SMA: Bearish | May 29, 2026 | 5 months ago |
| SMA: Bullish | May 28, 2026 | 5 months ago |
| SMA: Bearish | May 26, 2026 | 5 months ago |
| SMA: Bullish | May 22, 2026 | 5 months ago |
| SMA: Bullish | May 22, 2026 | 5 months ago |
| MACD: Buy Signal | May 22, 2026 | 5 months ago |
| RSI: Overbought | May 22, 2026 | 5 months ago |
| MACD: Sell Signal | May 12, 2026 | 5 months ago |
| SMA: Bearish | May 8, 2026 | 5 months ago |
| SMA: Bullish | May 7, 2026 | 5 months ago |
| MACD: Buy Signal | Apr 13, 2026 | 6 months ago |
| RSI: Oversold | Mar 18, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 16, 2026 | 7 months ago |
| SMA: Bearish | Mar 13, 2026 | 7 months ago |
| SMA: Bullish | Mar 10, 2026 | 7 months ago |
| RSI: Oversold | Dec 23, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 22, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 18, 2025 | 10 months ago |
| RSI: Oversold | Dec 16, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 9, 2025 | 10 months ago |
| RSI: Oversold | Dec 2, 2025 | 11 months ago |
| MACD: Sell Signal | Dec 1, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 28, 2025 | 11 months ago |
| RSI: Oversold | Nov 17, 2025 | 11 months ago |
| SMA: Bearish | Oct 15, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 13, 2025 | 1 year ago |
| SMA: Bullish | Oct 6, 2025 | 1 year ago |
| SMA: Bearish | Oct 3, 2025 | 1 year ago |
| SMA: Bullish | Sep 24, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 9, 2025 | 1 year ago |
| RSI: Oversold | Aug 26, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 20, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 15, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 13, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 12, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 30, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 16, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 15, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 9, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 8, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 1, 2025 | 1 year ago |
| SMA: Bearish | Jun 5, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 5, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 2, 2025 | 1 year ago |
| SMA: Bullish | May 28, 2025 | 1 year ago |
| SMA: Bearish | May 27, 2025 | 1 year ago |
| SMA: Bullish | May 23, 2025 | 1 year ago |
| SMA: Bearish | May 21, 2025 | 1 year ago |
| MACD: Sell Signal | May 8, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 21, 2025 | 1 year ago |
| SMA: Bullish | Apr 17, 2025 | 1 year ago |
| SMA: Bearish | Apr 16, 2025 | 1 year ago |
| SMA: Bullish | Apr 14, 2025 | 1 year ago |
| SMA: Bearish | Apr 10, 2025 | 1 year ago |
| SMA: Bullish | Apr 7, 2025 | 1 year ago |
| SMA: Bearish | Apr 4, 2025 | 1 year ago |
| SMA: Bullish | Apr 3, 2025 | 1 year ago |
| SMA: Bearish | Apr 1, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 1, 2025 | 1 year ago |
| RSI: Overbought | Mar 20, 2025 | 1 year ago |
| SMA: Bullish | Mar 18, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 10, 2025 | 1 year ago |
| SMA: Bearish | Feb 13, 2025 | 1 year ago |
| SMA: Bullish | Feb 12, 2025 | 1 year ago |
| SMA: Bearish | Feb 10, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 10, 2025 | 1 year ago |
| SMA: Bullish | Feb 6, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 6, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 5, 2025 | 1 year ago |
| SMA: Bearish | Feb 4, 2025 | 1 year ago |
| SMA: Bullish | Feb 3, 2025 | 1 year ago |
| SMA: Bearish | Jan 31, 2025 | 1 year ago |
| SMA: Bullish | Jan 27, 2025 | 1 year ago |
| RSI: Oversold | Dec 9, 2024 | 1 year ago |
Key statistics
- Market cap
- 25.94M
- Enterprise value
- 35.14B
- Trailing P/E
- 0.00
- Forward P/E
- -0.29
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -2.58
- Beta
- 0.95
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -7.51M
- Total cash
- 4.18M
- Total debt
- 1.00M
- Return on equity
- 0.00%
- Shares outstanding
- 26.47M
- Short % of float
- 0.23%
- 50-day average
- 1.78
- 200-day average
- 2.41
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
May 6, 2024
Expected May 6, 2024. Consensus EPS estimate 0.00.
Financials — quick view
AKTX Revenue — quarterly 0
AKTX Net income — quarterly -4.81M
AKTX EPS — quarterly 0.00
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 6, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Oct 3, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
| Jul 19, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
| May 15, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
| Jan 6, 2023 | Sep 1, 2022 | 0.00 | — | — | — |
| Sep 27, 2022 | Jun 1, 2022 | 0.00 | -2.00 | — | — |
About Akari Therapeutics, Plc
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- akaritx.com
News
- Akari Therapeutics to Highlight Novel RNA-Splicing ADC Payload Strategy at the 3rd Annual ADC Payload Summit
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- Why XCF Global Shares Are Trading Higher By Around 65%; Here Are 20 Stocks Moving Premarket
- Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- Akari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and Partnering
- Akari Therapeutics Submits PCT/US2026/45955 To Expand Its IP Portfolio
- Akari Therapeutics Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in Cancers
- Akari Therapeutics PLC (NASDAQ:AKTX) Short Interest Update
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Your note
Sign in to keep a note on AKTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DICICCO WENDY FRANCES | Chief Financial Officer | Stock Award(Grant) | Apr 30, 2024 | 158,474,000 |
| PATEL SAMIR RASHMIKANT | Director | Stock Award(Grant) | Jun 27, 2024 | 3,502,890,000 |
| PRUDO-CHLEBOSZ RAYMOND M.D. | Director | Stock Award(Grant) | Dec 1, 2024 | 4,916,600,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Omnia Family Wealth, LLC | 0.33% | 87,628 | 85.88K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.13% | 33,260 | 32.59K | Sep 29, 2024 |
| Cerity Partners LLC | 0.09% | 23,643 | 23.17K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.07% | 18,069 | 17.71K | Sep 29, 2024 |
| Cresset Asset Management, LLC | 0.07% | 18,408 | 18.04K | Sep 29, 2024 |
| Cornerstone Planning Group LLC | 0.00% | 5 | 4 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.01% | 1,512 | 1.48K | Oct 30, 2024 |